What changed
$NVDA — AVOID 📊 | 6 MONTHS THESIS
🎯 FQ1 FY2027 (ends Apr) | reported May 20 | Rev $81.6B | EPS $1.87 vs $1.77 🟢 | Margin 69.0%
💡 The market prices NVDA at a premium (30.6x trailing P/E) relative to its peer median (19.5x) and expects only -1.8% FCF growth (reverse DCF). While the company continues to beat estimates, the bar is extremely high; any growth deceleration or margin compression could trigger sharp multiple contraction.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 9/10
📊 Valuation: rich — current P/E 30.6x vs. peer band 9.2x–45.2x (median 19.5x); forward P/E ~22.5x; reverse DCF implies -1.8% FCF growth; base case DCF-driven...
🔮 Catalyst: Q1 FY27 earnings beat (5.5% EPS beat) already released
💰 Entry: $183, stop $150, target $248
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/NVDA0611